The anti-obesity effects of CB1R antagonists could be attributed to a reduction in food intake (anorexia) due to the blockade of hypothalamic CB1Rs coupled with an increase in energy expenditure caused by peripheral CB1R blockade (Chorvat et al., 2012; Kaur et al., 2016; Lu et al., 2016). The gene discussed is CNR1; the disease is Anorexia.